Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06449001 | RECRUITING | Paroxysmal Nocturnal Hemoglobinuria

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Sponsor:

Alexion Pharmaceuticals, Inc.

Brief Summary:

The primary objective of this study is to evaluate efficacy of danicopan as add-on treatment to ravulizumab or eculizumab as assessed by hemoglobin (Hgb) change from Baseline at Week 12 in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH) and clinically significant extravascular hemolysis (CS-EVH).

Condition or disease

Paroxysmal Nocturnal Hemoglobinuria

PNH

Extravascular Hemolysis

Intervention/treatment

Danicopan

Phase

PHASE3

Study Type : INTERVENTIONAL
Estimated Enrollment : 6 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis
Actual Study Start Date : 2025-09-30
Estimated Primary Completion Date : 2027-07-19
Estimated Study Completion Date : 2028-07-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 12 Years to 17 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Confirmed diagnosis of PNH.
  • * CS-EVH defined by: Anemia: Hgb ≤ 10.5 g/dL, and absolute reticulocyte count ≥ 100 × 109/L
  • * Treated with ravulizumab or eculizumab for at least 12 weeks immediately preceding Day 1, the dose received should be stable during this period, and there should be no anticipated changes in dosage or interval during the first 12 weeks of this study.
  • * all participants must be vaccinated against meningococcal infection from serogroups A, C, W, and Y and serogroup B within 3 years prior to, or at least 14 days prior to Day 1
  • * vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae
Exclusion Criteria
  • * Platelet count \< 30000/μL or there is a need for platelet transfusions.
  • * ANC \< 500/μL.
  • * Clinically significant laboratory abnormalities related to liver function, including
    • * ALT \> 2 × ULN or ALT \> 3 × ULN for participants with documented liver iron overload defined by serum ferritin values ≥ 500 ng/mL.
    • * Direct bilirubin \> 2 × ULN, unless, in the Investigator's opinion, is due to hemolysis or Gilbert's syndrome based on medical history.
    • * Current evidence of biliary cholestasis.
    • * Known aplastic anemia or other bone marrow failure that requires HSCT or other therapies, including anti-thymocyte globulin and immunosuppressants unless the dosage of immunosuppressant has been stable for at least 12 weeks before Day 1 and is expected to remain stable through Week 12.
    • * History of a major organ transplant (eg, heart, lung, kidney, liver) or HSCT.
    • * Known or suspected complement deficiency.
    • * Active bacterial or viral infection, a body temperature \> 38°C on 2 consecutive daily measures, evidence of other infection, or history of any febrile illness within 14 days prior to first study intervention administration.
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Location Details

NCT06449001

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

France,

Research Site

Paris, France, 77019